Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Feb 15, 2025; 17(2): 100908
Published online Feb 15, 2025. doi: 10.4251/wjgo.v17.i2.100908
Development and validation of a nomogram prediction model for overall survival in patients with rectal cancer
Ling Liang, Xiao-Sheng Li, Ze-Jun Huang, Zu-Hai Hu, Qian-Jie Xu, Yu-Liang Yuan, Wei Zhang, Hai-Ke Lei
Ling Liang, Ze-Jun Huang, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing 400030, China
Xiao-Sheng Li, Qian-Jie Xu, Yu-Liang Yuan, Wei Zhang, Hai-Ke Lei, Chongqing Cancer Multi-omics Big Data Application Engineering Research Center, Chongqing University Cancer Hospital, Chongqing 400030, China
Zu-Hai Hu, Department of Health Statistics, School of Public Health, Chongqing Medical University, Chongqing 400016, China
Co-first authors: Ling Liang and Xiao-Sheng Li.
Co-corresponding authors: Wei Zhang and Hai-Ke Lei.
Author contributions: Liang L and Li XS conceived and designed the study; Hu ZH performed the analysis and interpretation of the statistics; Liang L and Huang ZJ wrote the initial drafts of the paper; Xu QJ handled the data collection and statistical analysis; Zhang W and Lei HK revised the article and approved publishing the final version. All the authors contributed equally to the manuscript and read and approved the final version of the manuscript. Liang L and Li XS contributed equally to this work as co-first authors. Prof. Zhang W, who is affiliated with the Department of Gastroenterology, identified a pressing need for a more scientifically rigorous, comprehensive, and practical model that integrates clinically relevant indicators to aid in decision-making processes. Prof. Lei HK primarily oversees the follow-up care of cancer patients. Consequently, Prof. Zhang W and Prof. Lei HK collaborated to design the study, revise the manuscript, and approve the final version for publication. They are jointly designated as co-corresponding authors.
Institutional review board statement: This study adhered to the guiding principles of the Helsinki Declaration and received approval from the Ethics Committee of Chongqing University Cancer Hospital (CZLS2023337-A).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: We have no financial relationships to disclose.
Data sharing statement: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hai-Ke Lei, Associate Professor, Chongqing Cancer Multi-omics Big Data Application Engineering Research Center, Chongqing University Cancer Hospital, No. 181 Hanyu Road, Shapingba District, Chongqing 400030, China. tohaike@163.com
Received: August 30, 2024
Revised: October 30, 2024
Accepted: November 14, 2024
Published online: February 15, 2025
Processing time: 141 Days and 8 Hours
Core Tip

Core Tip: This study developed and validated a novel prognostic nomogram for rectal cancer, incorporating demographic, clinicopathological, haematological, and follow-up data. The prognostic factors include Karnofsky performance status, age, sex, TNM stage, chemotherapy, surgery, targeted therapy, β2-microglobulin, lactate dehydrogenase (LDH), and neutrophil-to-lymphocyte ratio. Compared to the TNM staging system, the nomogram demonstrated high accuracy in predicting 1-year, 3-year, and 5-year overall survival (C-index 0.80), with excellent generalizability and clinical utility. It provides a reliable tool for personalized interventions. However, further research is needed to explore the role of β2-microglobulin and LDH in the progression of rectal cancer and to validate the model.